Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial )--Aerpio Therapeutics, a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced top-line results from its TIME-2 study of A... )--Radian Group Inc. today announced that it will hold a conference call on Wednesday, July 22, 2015, at 10:00 a.m. Eastern time to discuss the company's second quarter ... )--Dyax Corp. will host a webcast and conference call, including an open question and answer session, Wednesday, July 29, 2015. During the call, manag... )--Zocere has been issued a US patent for its brain-saving drug candidate for stroke and other traumatic brain injuries.
↧